Fbae Logo
Home | | Support Us | Contact Us
Goals & Objectives False Propaganda Special Topics Important Publications Important Links Events News Biosafety
Fbae Header Home




Podcast Alert: Clinical Trial Ethics in the Developing World
PODCAST: "Clinical Trial Ethics in the Developing World"

Jonathan Kimmelman, Ph.D., Assistant Professor in the Biomedical Ethics Unit/Social Studies of Medicine Department, McGill University, is interviewed by GEN's Editor in Chief, John Sterling.

WHEN: August 7 - August 14, 2008

Early-stage gene therapy clinical trials are recruiting patients from the developing world, providing medically deprived populations with access to interventions that show promise. The effects of these early studies on humans, however, are largely unknown.

According to commentary by bioethicists at Carnegie Mellon (Alex John London, Ph.D.) and McGill University (Jonathan Kimmelman, Ph.D.) published in the July 5 issue of The Lancet, the practice may be inconsistent with international ethics guidelines on justice.

During this week's GEN podcast, Dr. Kimmelman elaborates on this perceived disparity. He also identifies two specific questions surrounding international research that he and Dr. London believe have received scant attention. Dr. Kimmelman discusses why researchers are increasingly looking to the developing world as a source of clinical trial participants and describes a number of key concerns about carrying out early-stage studies in developing nations, including those involving gene therapy, versus conducting Phase II and III investigations. He offers some well thought out advice to companies and scientists planning to carry out early-stage trials in the developing world.

About GEN
Genetic Engineering & Biotechnology News
http://cl.exct.net/?qs=128548628759b176688f30cb10dba02e5d804371f3da22c6738e637a03d195ba  is the most widely read publication in the biotechnology industry and the only high-frequency publication focused on international bioindustry news. Established in 1981, GEN is also the first biotechnology trade publication, having covered the industry since its inception.

About Mary Ann Liebert, Inc. publishers
GEN is published by Mary Ann Liebert, Inc.
http://cl.exct.net/?qs=c5b4d49312c3d9dd0d4e6292424c03745411484863c6ee7868782182c012c00e a privately held, fully integrated media company known for developing authoritative, peer-reviewed journals in cutting-edge areas of bioscience and medicine, engineering, law, and business.

Contact Us to Subscribe:
Sign up for a subscription to GEN

To advertise:
Maximize your print and/or online opportunities

For editorial:

John Sterling <mailto:editor@genengnews.com&gt; , Editor in Chief

For business and partnership opportunities:

Business Development <mailto:jboyce@genengnews.com; hmatysko@genengnews.com

This email was sent by: Genetic Engineering & Biotechnology News 140 Huguenot St New Rochelle, NY, 10801, USA

Update Your Profile
http://cl.exct.net/?qs=476c0fa4ee081a7c323f844e8a4867a469fced4659c7acb7fe66b95232a54b74  or Unsubscribe

IMPORTANT! Make sure you receive your chosen GEN e-Newsletters.
Add update@genengnews.com to your Address Book or Safe Senders List. It's easy! Click HERE
http://cl.exct.net/?qs=9b54f69f96338941b413ce7516e4de0128cb2d3c1989a800b4d9529e40c4db87  for instructions.